FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Pfizer, Wyeth merger bad idea?

Tools

Fortune writer John Simons opines that a rumored merger of Pfizer and Wyeth would be all wrong for both companies. In his view, a merger would amount to a marriage of weaknesses. Pfizer needs blockbusters to overcome looming patent expirations and Wyeth has recently been failing to deliver.

"Would the idea behind the merger be that misery loves company?" says Standard & Poors pharma analyst Herman Saftlas. "Most mergers in this sector haven't panned out from an earnings growth perspective. But even worse, these two companies are in the same boat."

- read Simon's opinion piece

Related Articles:
Wyeth buyout a good deal for Pfizer? Report
What's next for Pfizer? Report
Wyeth stumbles badly trying to develop new drugs. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Mergers and Acquisitions   Pfizer   Wyeth   patent expirations   drug development